Eli Lilly's most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $180.00 short put and a strike $175.00 long put offers a potential 12.61% return on risk over the next 9 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $180.00 by expiration. The full premium credit of $0.56 would be kept by the premium seller. The risk of $4.44 would be incurred if the stock dropped below the $175.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.
The RSI indicator is at 41.96 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
CVS Health: A Rare Underpriced Health Care Blue-Chip
Fri, 02 Apr 2021 16:40:45 +0000
Despite a phenomenal performance in 2020, the company's stock trades at a discount
Lilly to Host Sustainability Webcast to Provide Overview of Environmental, Social and Governance (ESG) Efforts
Thu, 01 Apr 2021 12:00:00 +0000
Eli Lilly and Company (NYSE: LLY) will host a webcast for the investment community, media and the general public on May 4, 2021 to provide an overview of the company's strong commitment to sustainability efforts in the areas of Environmental, Social and Governance (ESG). The webcast will include remarks from David A. Ricks, Lilly chairman and chief executive officer, as well as other senior Lilly leaders. The event will run from 10:30 a.m. to noon EDT.
Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care
Wed, 31 Mar 2021 12:30:00 +0000
Approximately 9 in 10 specialists agree that people with type 2 diabetes whose healthcare professionals (HCPs) collaborate tend to have better outcomes than those whose HCPs do not, while the top barrier to more collaboration among specialists is lack of time. This barrier is prevalent across HCP specialties with more than 80 percent of endocrinologists, cardiologists and nephrologists wishing they had the time to more closely track patients when they see multiple providers. The findings are from a survey of 1,000 U.S. healthcare professionals (i.e., primary care physicians, cardiologists, endocrinologists, nephrologists and nurse practitioners), conducted by The Harris Poll on behalf of Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY), as part of the Unleashing the Truth About Diabetes and Heart Disease® campaign, which aims to increase awareness of the role of specialists in the treatment of diabetes and related chronic conditions and promote multidisciplinary collaboration.
Could Pfizer's and Lilly's Long-Awaited Osteoarthritis Drug Flop?
Wed, 31 Mar 2021 11:31:00 +0000
Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) have worked together for years on the development of an osteoarthritis pain drug, tanezumab. In this Motley Fool Live video recorded on March 24, 2021, Motley Fool contributors Keith Speights and Brian Orelli talked about the hurdles the two companies must jump to win U.S. approval for the drug.
Lilly/Vir's Cocktail COVID-19 Therapy Meets Study Endpoint
Tue, 30 Mar 2021 13:01:01 +0000
Eli Lilly (LLY), Vir Biotechnology and Glaxo are developing a combination of their respective monoclonal antibodies as a potential treatment for mild-to-moderate COVID-19 patients.
Also on Market Tamer…
Follow Us on Facebook